238 related articles for article (PubMed ID: 18348680)
21. Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain.
Bondarenko O; Saarma M
Front Cell Neurosci; 2021; 15():682597. PubMed ID: 34149364
[TBL] [Abstract][Full Text] [Related]
22. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
Kelly MJ; O'Keeffe GW; Sullivan AM
Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
[TBL] [Abstract][Full Text] [Related]
23. CDNF Protein Therapy in Parkinson's Disease.
Huttunen HJ; Saarma M
Cell Transplant; 2019 Apr; 28(4):349-366. PubMed ID: 30947516
[TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
Nutt JG; Burchiel KJ; Comella CL; Jankovic J; Lang AE; Laws ER; Lozano AM; Penn RD; Simpson RK; Stacy M; Wooten GF;
Neurology; 2003 Jan; 60(1):69-73. PubMed ID: 12525720
[TBL] [Abstract][Full Text] [Related]
25. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease.
Lapchak PA; Gash DM; Jiao S; Miller PJ; Hilt D
Exp Neurol; 1997 Mar; 144(1):29-34. PubMed ID: 9126148
[TBL] [Abstract][Full Text] [Related]
26. GDNF therapy for Parkinson's disease.
Hong M; Mukhida K; Mendez I
Expert Rev Neurother; 2008 Jul; 8(7):1125-39. PubMed ID: 18590482
[TBL] [Abstract][Full Text] [Related]
27. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
[TBL] [Abstract][Full Text] [Related]
28. Prospects for the treatment of Parkinson's disease using neurotrophic factors.
Hurelbrink CB; Barker RA
Expert Opin Pharmacother; 2001 Oct; 2(10):1531-43. PubMed ID: 11825297
[TBL] [Abstract][Full Text] [Related]
29. GDNF delivery for Parkinson's disease.
Patel NK; Gill SS
Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
[TBL] [Abstract][Full Text] [Related]
30. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.
Garbayo E; Ansorena E; Lana H; Carmona-Abellan MD; Marcilla I; Lanciego JL; Luquin MR; Blanco-Prieto MJ
Biomaterials; 2016 Dec; 110():11-23. PubMed ID: 27697668
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy.
Delgado-Minjares KM; Martinez-Fong D; Martínez-Dávila IA; Bañuelos C; Gutierrez-Castillo ME; Blanco-Alvarez VM; Cardenas-Aguayo MD; Luna-Muñoz J; Pacheco-Herrero M; Soto-Rojas LO
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769132
[TBL] [Abstract][Full Text] [Related]
32. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
33. Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.
Aly AE; Waszczak BL
Expert Opin Drug Deliv; 2015; 12(12):1923-41. PubMed ID: 26289676
[TBL] [Abstract][Full Text] [Related]
34. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R; Gash DM
J Neurol; 1998 Nov; 245(11 Suppl 3):P35-42. PubMed ID: 9808338
[TBL] [Abstract][Full Text] [Related]
35. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
eNeuro; 2017; 4(1):. PubMed ID: 28303260
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.
Kordower JH; Palfi S; Chen EY; Ma SY; Sendera T; Cochran EJ; Cochran EJ; Mufson EJ; Penn R; Goetz CG; Comella CD
Ann Neurol; 1999 Sep; 46(3):419-24. PubMed ID: 10482276
[TBL] [Abstract][Full Text] [Related]
37. Neurotrophic and neurorescue effects of Echinacoside in the subacute MPTP mouse model of Parkinson's disease.
Zhao Q; Gao J; Li W; Cai D
Brain Res; 2010 Jul; 1346():224-36. PubMed ID: 20478277
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
39. GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution.
Grondin R; Littrell OM; Zhang Z; Ai Y; Huettl P; Pomerleau F; Quintero JE; Andersen AH; Stenslik MJ; Bradley LH; Lemmon J; O'Neill MJ; Gash DM; Gerhardt GA
Neuropharmacology; 2019 Mar; 147():28-36. PubMed ID: 29857941
[TBL] [Abstract][Full Text] [Related]
40. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
